Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Nov 28:6:37933.
doi: 10.1038/srep37933.

The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients

Minghui Zhang  1 , Yuandi Dong  2 , Haitao Liu  3 , Yan Wang  4 , Shu Zhao  1 , Qijia Xuan  1 , Yan Wang  1 , Qingyuan Zhang  1
Affiliations

The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients

Minghui Zhang et al. Sci Rep. .

Abstract

The prognostic value of programmed death-ligand 1 (PD-L1) in gastric cancer (GC) remains controversial. To clarify this problem, we performed a meta-analysis of research studies identified in the PubMed, EMBASE and the Cochrane Library databases. A total of 1,901 patients in 10 studies were enrolled in this meta-analysis, and the pooled hazard ratio (HR) of 1.64 (95% CI 1.11 to 2.43; P = 0.01) indicated that PD-L1 expression is associated with a shorter overall survival (OS). The pooled odds ratios (ORs) indicated that PD-L1 expression was associated with tumour size (OR = 1.87, 95% CI 1.25 to 2.78; P = 0.002) and lymph node status (OR = 2.17, 95% CI 1.04 to 4.52; P = 0.04). However, PD-L1 had no correlation with gender, age, cancer location, differentiation, depth of invasion, and tumour stage. This meta-analysis indicates that PD-L1 expression is a valuable predictor of the prognosis of patients with GC. PD-L1 expression could be used for identifying a subgroup of patients, who would potentially benefit from targeted therapy against PD-1 or PD-L1. Well-designed large-cohort studies are needed to confirm these findings.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Flow Chart of Study Selection.
Figure 2
Figure 2. Forest plot describing the association between PD-L1 expression and OS of patients with gastric cancer.
Figure 3
Figure 3. Forest plot describing subgroup analysis of the association between PD-L1 expression and OS according to immunohistochemistry cutoff value.
(A) Percentage (cutoff value 10%), (B) percentage (cutoff value 51%).
Figure 4
Figure 4
Forest plots for the association between PD-L1 expression and clinicopathological features (A) gender, (B) age, (C) cancer location, (D) differentiation, (E) tumor size, (F) dept of invasion, (G) lymph node metastasis, H. stage.
Figure 5
Figure 5. Egger’s and Begg’s funnel plot with 95% confidence intervals for OS publication bias testing.
Figure 6
Figure 6. Funnel blot was designed to visualize a potential publication bias for PD-L1 expression and gender.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siegel R. L., Miller K. D. & Jemal A. Cancer statistics, 2016. CA Cancer J Clin 66, 7–30 (2016). - PubMed
    1. Ajani J. A. Gastroesophageal cancers: progress and problems. J Natl Compr Canc Netw 6, 813–814 (2008). - PubMed
    1. Dittmar Y. & Settmacher U. Individualized treatment of gastric cancer: Impact of molecular biology and pathohistological features. World J Gastrointest Oncol 7, 292–302 (2015). - PMC - PubMed
    1. Zou W., Wolchok J. D. & Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med 8, 328rv324 (2016). - PMC - PubMed
    1. Hansen J. D. et al.. The B7 family of immunoregulatory receptors: a comparative and evolutionary perspective. Mol Immunol 46, 457–472 (2009). - PubMed

Publication types